Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), María Vidal(Inserm), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Juan Miguel Cejalvo(Universitat de València), Claudette Falato(Karolinska Institutet), Sònia Pernas, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Juan Antonio Guerra(Hospital Universitario de Fuenlabrada), J.M. Ferrero-Cafiero(Solti), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Pang‐Dian Fan(Daiichi Sankyo (United States)), Mireia Margelí Vila(Institut Català d'Oncologia), Patricia Galván(Vall d'Hebron Institute of Oncology), Stephen Esker(Daiichi Sankyo (United States)), Francisco Javier Salvador-Bofill(Solti), Fumitaka Suto(Daiichi Sankyo (United States)), Andreu Òdena(Vall d'Hebron Institute of Oncology), Dalila Sellami(Daiichi Sankyo (United States)), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Martín Espinosa-Bravo(Universitat Autònoma de Barcelona), Ana Vivancos(Vall d'Hebron Institute of Oncology), Violeta Serra(Vall d'Hebron Institute of Oncology), Eva Ciruelos(Hospital Universitario 12 De Octubre), Yann Izarzugaza(Hospital Universitario Fundación Jiménez Díaz), Aleix Prat(Hospital Clínic de Barcelona), Josefina Cruz(Hospital Universitario de Canarias), Judith Matito(Vall d'Hebron Institute of Oncology), Francisco Pardo(Oryzon Genomics (Spain)), Anu Santhanagopal(Daiichi Sankyo (United States)), Míriam Arumí(Vall d'Hebron Hospital Universitari), Ana María Luna Barrera(HM Hospitales)
Cited by 23
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k